학술논문

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.
Document Type
article
Source
The Journal of antimicrobial chemotherapy. 70(2)
Subject
ANRS Resistance AC11 Group
Humans
HIV-1
HIV Infections
Nervous System Diseases
Anti-HIV Agents
Antiretroviral Therapy
Highly Active
Microbial Sensitivity Tests
Viral Load
Drug Resistance
Viral
Genotype
Mutation
Adult
Middle Aged
Female
Male
ARV
CSF
HIV
resistance
Antiretroviral Therapy
Highly Active
Drug Resistance
Viral
Microbiology
Medical Microbiology
Pharmacology and Pharmaceutical Sciences
Language
Abstract
OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.